TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06049303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paraffin wax bath therapy and Maitland joint mobilization techniques
Description: In group A Patients will be treated with paraffin wax bath 20 minutes (before any physical therapy treatment)~* (Apply a few drops of olive oil into the skin of the area. Dip/pour knee joint area into the wax and leave it in for a few seconds until a layer forms over the area. Wait for the wax to dry. Repeat this process until you have at least 10 layers of wax area to be treated.)~* Joint mobilization technique (8-12 glides at knee joint, mobilization grade-I and grade-II will be used for pain management and relaxation, while grade III for improvement in the PROM at knee joint) will be given 4 times a week for 6 weeks (The patient will be positioned in supine lying with the knee slightly flexed and a prop placed under the distal femur. The stabilizing hand will be used to prop the distal femur and the mobilizing hand is placed over the proximal tibia just below the tibial tuberosity. The mobilization itself will be performed by a force perpendicular to the line of the tibia.)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maitland knee joint mobilization
Description: Group B will have (8-12 glides at knee joint, mobilization grade-I and grade-II will be used for pain management and relaxation, while grade III for improvement in the PROM at knee joint) 4 times a week for 6 weeks.~Mobilization procedure will be same as above
Study: NCT05383716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Two to four cycles of neoadjuvant chemotherapy in combination with pembrolizumab will be administered before surgery, followed by another one to two cycles of chemotherapy plus pembrolizumab after surgery (4 cycles neoadjuvant/adjuvant chemotherapy in total ) then use pembrolizumab monotherapy for up to 1 year.
Study: NCT05905367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Symptom-inhibited IV fentanyl induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Opioid agonist therapy (OAT) with methadone at starting doses established by symptom-inhibited IV fentanyl induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Slow-release oral morphine
Description: Opioid agonist therapy (OAT) with SROM at starting doses established by symptom-inhibited IV fentanyl induction
Study: NCT05114499

Intervention type: DRUG
Intervention: Donepezil
Description: Donepezil 5mg qd

Intervention type: DRUG
Intervention: Donepezil
Description: Donepezil 5mg qd

Intervention type: DRUG
Intervention: GV-971
Description: GV-971 450mg bid

Intervention type: DRUG
Intervention: GV-971
Description: GV-971 450mg bid
Study: NCT04512456

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Exercise training performed during 12 weeks, 3 sessions per week of 60 minutes of strength and aerobic exercises.
Study: NCT05792475

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Define Standard of Truth (SOT) by Taihao Breast Cancer Diagnostic Software
Description: TaiHao Breast Cancer Diagnostic Software independently define standard of truth (SOT) about108 cases.
Study: NCT05971199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib:5 mg capsule orally once daily on day 1-21 in 28-day cycles；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab: 200 mg i.v. every 3 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization（TACE）
Description: Transcatheter arterial chemoembolization（TACE）
Study: NCT05671822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811；SHR-1701；capecitabine；oxaliplatin
Description: (Arm 1A) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion; (Arm 1B) Drug: SHR-A1811,administered as an IV infusion Drug：capecitabine, administered orally； (Arm 1C) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion Drug：capecitabine, administered orally； (Arm 1D) Drug: SHR-A1811,administered as an IV infusion Drug：capecitabine, administered orally； Drug：oxaliplatin，administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811；SHR-1701；capecitabine；oxaliplatin
Description: (Arm 1A) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion; (Arm 1B) Drug: SHR-A1811,administered as an IV infusion Drug：capecitabine, administered orally； (Arm 1C) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion Drug：capecitabine, administered orally； (Arm 1D) Drug: SHR-A1811,administered as an IV infusion Drug：capecitabine, administered orally； Drug：oxaliplatin，administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811；SHR-1701；capecitabine；oxaliplatin
Description: (Arm 1A) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion; (Arm 1B) Drug: SHR-A1811,administered as an IV infusion Drug：capecitabine, administered orally； (Arm 1C) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion Drug：capecitabine, administered orally； (Arm 1D) Drug: SHR-A1811,administered as an IV infusion Drug：capecitabine, administered orally； Drug：oxaliplatin，administered as an IV infusion
Study: NCT06224179

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound guided subcostal TAP block
Description: patients will be randomly divided into two groups using a computer generated random number chart.~Group A received ultrasound guided subcostal TAP block,
Study: NCT05671822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811；SHR-1701；capecitabine；oxaliplatin
Description: (Arm 1A) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion; (Arm 1B) Drug: SHR-A1811,administered as an IV infusion Drug：capecitabine, administered orally； (Arm 1C) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion Drug：capecitabine, administered orally； (Arm 1D) Drug: SHR-A1811,administered as an IV infusion Drug：capecitabine, administered orally； Drug：oxaliplatin，administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811；SHR-1701；capecitabine；oxaliplatin
Description: (Arm 2A) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion; (Arm 2B) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion Drug：capecitabine, administered orally； (Arm 2C) Drug: SHR-A1811,administered as an IV infusion Drug：capecitabine, administered orally； Drug：oxaliplatin，administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811；SHR-1701；capecitabine；oxaliplatin
Description: (Arm 2A) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion; (Arm 2B) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion Drug：capecitabine, administered orally； (Arm 2C) Drug: SHR-A1811,administered as an IV infusion Drug：capecitabine, administered orally； Drug：oxaliplatin，administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811；SHR-1701；capecitabine；oxaliplatin
Description: (Arm 2A) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion; (Arm 2B) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion Drug：capecitabine, administered orally； (Arm 2C) Drug: SHR-A1811,administered as an IV infusion Drug：capecitabine, administered orally； Drug：oxaliplatin，administered as an IV infusion
Study: NCT06541665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4059
Description: Specified dose, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Specified dose on specified days
Study: NCT04155008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: If the patient's prognosis is extremely poor (less than 12 weeks expected survival, based on discussion with the patient's treating physicians) and there is no additional disease modifying therapy planned, the patient will be prescribed 4mg dexamethasone (which is FDA approved), once daily, to be taken orally in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: If the patient has a history of marijuana use or has tried it in the past and had a positive experience with it, then the patient will be prescribed dronabinol (which is FDA approved) 2.5mg, twice daily before meals.
Study: NCT05863585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum)
Description: 100µg
Study: NCT06541665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procarbazine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Specified dose on specified days
Study: NCT06181903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional freedom technique group
Description: Control group
Study: NCT04824599

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PECS II
Description: Pectoral nerves block (PECS II) is performed with the help of ultrasound. Two injection are performed in two fascial planes. One between pectoralis major muscle and serratus anterior muscle. Second one between pectoralis major and minor muscles.
Study: NCT04155008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: If the patient does not have any history of marijuana use, mirtazapine will be prescribed. If the patient is under the age of 70, then the patient would be prescribed 15mg of mirtazapine (which is FDA approved), once daily, to be taken orally at bedtime. For geriatric population (if the patient is over the age of 70), then the patient would be prescribed 7.5mg of mirtazapine, once daily to be taken orally at bedtime.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Intervention
Description: Nutrition intervention will be in accordance with the Academy of Nutrition and Dietetics guidelines. The intervention will involve purposefully planned action(s) designed with the intent of changing a nutrition-related behavior, risk factor, environmental condition, or aspect of health status

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Intervention
Description: Nutrition intervention will be in accordance with the Academy of Nutrition and Dietetics guidelines. The intervention will involve purposefully planned action(s) designed with the intent of changing a nutrition-related behavior, risk factor, environmental condition, or aspect of health status
Study: NCT06224179

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound guided combined posterior and subcostal TAP block
Description: patients will be randomly divided into two groups using a computer generated random number chart.~Group B received ultrasound guided combined posterior and subcostal TAP block,
Study: NCT04617730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepitel® film
Description: This study is a comparative study between the standard procedure, which is to prescribe a hydro-active colloidal gel called Flamigel® to be applied to the irradiated area, and the use of Mepitel® Film.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flamigel®
Description: The control arm will be treated according to the standard of care.
Study: NCT04824599

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic infiltration
Description: Ropivacaine is administered by surgeon prior to scrubbing and following the removal of the tumor.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneus local anesthetic infiltration
Description: Ropivacaine is administered by the surgeon at the end of surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Local anesthetic ropivacaine is administered in both study arms according to the study protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Local anesthetic ropivacaine is administered in both study arms according to the study protocol

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bk medical Flex Focus 500 Ultrasound Machine
Description: Ultrasound with linear probe is performed. Using in-plane technique a correct placement of the injection needle is secured.
Study: NCT05119738

Intervention type: BIOLOGICAL
Intervention: Three doses of BNT162b2 (observational)
Description: BNT162b2 (COVID 19 mRNA vaccine)

Intervention type: BIOLOGICAL
Intervention: Two doses of Coronavac and one dose BNT162b2 (observational)
Description: BNT162b2 (COVID 19 mRNA vaccine) Coronavac (COVID 19 inactive vaccine)
Study: NCT06006481

Intervention type: OTHER
Intervention: Survey
Description: Extended Nordic Musculoskeletal Questionnaire Pain Management Inventory Maslach Burnout Scale Vocational Satisfaction Scale

Intervention type: OTHER
Intervention: Survey
Description: Extended Nordic Musculoskeletal Questionnaire Pain Management Inventory Maslach Burnout Scale Vocational Satisfaction Scale

Intervention type: OTHER
Intervention: Survey
Description: Extended Nordic Musculoskeletal Questionnaire Pain Management Inventory Maslach Burnout Scale Vocational Satisfaction Scale

Intervention type: OTHER
Intervention: Survey
Description: Extended Nordic Musculoskeletal Questionnaire Pain Management Inventory Maslach Burnout Scale Vocational Satisfaction Scale

Intervention type: OTHER
Intervention: Survey
Description: Extended Nordic Musculoskeletal Questionnaire Pain Management Inventory Maslach Burnout Scale Vocational Satisfaction Scale
Study: NCT05334576

Intervention type: OTHER
Group type: OTHER
Intervention: Crizanlizumab
Description: Crizanlizumab 5.0 mg/kg infusions will be administered over 24 months
Study: NCT05839366

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine
Description: Load dose of 0.25 mg/kg, and the fixed infusion rate of 0.15 mg/kg/h.The load dose will be injected intravenously within 1-2 minutes.Maintain the infusion at a fixed rate of 0.15 mg/kg/h for 72 hours; after 72 hours, change to a fixed rate infusion of 0.06 mg/kg/h.~Preparation: 46ml of saline + 4ml of eskeamine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: As a placebo,normal saline at the same dose as esketamine.Saline is also administered intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil + propofol
Description: Remifentanil + propofol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remifentanil + propofol
Description: Remifentanil + propofol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pain and Sedation Assessment
Description: RASS Score:~After randomization success, a baseline Richmond Agitation-Sedation Scale (RASS) score is obtained before administering the investigational drug. Pain assessments are conducted every 1 hour within the first 6 hours after the initiation of the intravenous loading dose of the investigational drug, every 4 hours within the first 24 hours, and subsequently every 8 hours until the end of the study. In addition to the fixed time points mentioned above, researchers may conduct RASS scoring at any time based on the subject's actual condition (excessive or inadequate sedation). (No further RASS scoring is performed once the subject is fully awake.)~CPOT Score:~CPOT（Critical-Care Pain Observation Tool）Pain assessments are conducted concurrently with RASS scoring.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Pain and Sedation Assessment
Description: RASS Score:~After randomization success, a baseline Richmond Agitation-Sedation Scale (RASS) score is obtained before administering the investigational drug. Pain assessments are conducted every 1 hour within the first 6 hours after the initiation of the intravenous loading dose of the investigational drug, every 4 hours within the first 24 hours, and subsequently every 8 hours until the end of the study. In addition to the fixed time points mentioned above, researchers may conduct RASS scoring at any time based on the subject's actual condition (excessive or inadequate sedation). (No further RASS scoring is performed once the subject is fully awake.)~CPOT Score:~CPOT（Critical-Care Pain Observation Tool）Pain assessments are conducted concurrently with RASS scoring.
Study: NCT05132218

Intervention type: DRUG
Intervention: Ensatinib
Description: Prospective, exploratory, single-arm, multi-center, real-world research
Study: NCT05983497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Care Skill Educational Intervention
Description: An evidence-based interactive self-care skill educational intervention that supports the clinical nurses to reduce compassion fatigue and increase the compassion satisfaction. The intervention will be delivered as 1-day activity-based educational training. The educational activity consists of the following content: the concept of compassionate fatigue, burnout awareness and recognition, eight dimensions of well-being, and followed by a demonstration of 7 guided self-care skill activities \*on practicing sleep hygiene, self-talk, gratitude practice, Journaling, breathing exercise, heartfulness relaxation, and heartfulness meditation. After the activity participants will develop their own self-care plan for practicing the self-care skills. At the end of the session, they will receive the instructional leaflet to practice the 7 self care skills that they gained from the educational activity.
Study: NCT05194800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Mirror Therapy
Description: Subjects will be offered the use of a Virtual Reality headset therapy game. Fiducial markers will be placed on the residual limb for tracking via front facing cameras on the Oculus Quest 2 and the sound limb movements will be duplicated (flipped for chirality) and mapped onto the residual limb to provide the appearance of their residual limb. The software will direct the subjects through a series of guided movements, stretches, and visualization exercises which last a total of 15 minutes. Afterwards the subjects will be given 5 minutes of unstructured time in the program to perform any of exercises or movements they desire in order to attempt to relieve their phantom limb pain.
Study: NCT05940974

Intervention type: OTHER
Intervention: Questionnaire administration
Description: All study participants will be surveyed with the EQ-5D-5L questionnaire to measure their quality of life indicators before the surgery and after the surgery (on 4 dates over a 1-year period); the DASH and ASES questionnaires to measure their functional outcomes before the surgery and after the surgery (on 4 dates over a 1-year period); the costs questionnaire to measure direct and indirect costs borne by patients because of their condition before the surgery and after the surgery (on 4 dates over a 1-year period).
Study: NCT04446468

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEACE
Description: The intervention consists of three synergistic components that work to support the patient after inpatient psychiatric discharge: 1) Brief educational component, where the patient receives a one-hour, one-on-one, personalized educational session on suicide prevention; 2) Seven regular contacts after discharge, where the study psychologist who delivered the brief educational visit will contact the patient to monitor the patient's symptoms, assess treatment adherence, review their safety plan, and assist the patient with engaging in care, if needed; and 3) Mobile app, which aims to improve the patient's social connectedness and provide additional educational materials on suicide.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Psychiatric Hospital Discharge Care
Description: Current VA standard discharge care includes five core elements. First, patients and their outpatient providers are required to be involved in discharge planning. Second, patients should be offered evidence-based treatments to address their mental health symptoms. Third, the inpatient team should work with the patient to complete a safety plan prior to discharge. Fourth, the inpatient team should arrange two follow-up care visits within 30 days of discharge. Fifth, the inpatient team in conjunction with the SPC assess whether patients are appropriate to be placed on the High Risk for Suicide List. Patients who are placed on the High Risk for Suicide List receive enhanced oversight as outlined in VA policy.
Study: NCT05188248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Participants will complete a single 30 minutes tDCS session targeting the left DLPFC while sitting in a comfortable position. At the end of the tDCS session possible side effects experienced during the tDCS session will be recorded along with their intensity (rated using the visual analogue scale, 0-10) and duration. The session can be aborted at any time for any reason if the participant wishes.The MINDD STIM tDCS system is composed of a management component, treatment module, single-use sponge patches and supporting patches, a headband to hold in position the sponge patches, and 2 cables. A trained study technician will program the stimulation device through the management component setting to the following stimulation parameters:Stimulation intensity: 2.0 mA or 1.5 mA; Stimulation duration: 30 minutes;Ramp up duration: 30 seconds (beginning of stimulation);Ramp down duration: 30 seconds (end of stimulation)
Study: NCT04942613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing Techniques
Description: Motivational Interviewing Techniques including but not limited to open-ended questions, reflection, affirmations, and summary will be used to build participant rapport, support behavior change (physical activity), and facilitate program engagement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy Interventions
Description: strengthening, balance, functional activities, stretching, breathing, aerobic endurance exercise

Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: Education on general health topics which may include the following: basic nutrition, stress reduction, sleep hygiene

Intervention type: OTHER
Group type: OTHER
Intervention: Qualitative Interview
Description: Qualitative interview to explore patient perspectives of the multicomponent telerehabilitation program (physical therapy, biobehavioral interventions, technology, and social support interventions) and how they contribute to program engagement and participation as well as changes in physical activity.